Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus rhamnosus M9
- Development stage
- Phase 2
- Lead developer
- Inner Mongolia Agricultural University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus M9 (also known as Probio-M9) is a specific probiotic bacterial strain originally isolated from human colostrum. It is developed as a live biotherapeutic product (LBP) intended to modulate the gut microbiome and enhance therapeutic outcomes in oncology and metabolic diseases. In clinical settings, it is being evaluated for its ability to synergize with immune checkpoint inhibitors (such as PD-1 inhibitors) and radiotherapy in patients with advanced digestive system malignancies, likely by promoting a pro-inflammatory tumor microenvironment through gut-immune axis modulation. Additionally, it is under investigation for its potential to improve glycemic control and cognitive function in patients with Type 1 Diabetes.
- Brand names
- Probio-M9Probio-M-9Probio-M 9
- Other names
- 鼠李糖乳杆菌M9L. rhamnosus M9
Beyond the preview
Go deeper on Lactobacillus rhamnosus M9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus rhamnosus M9.